HIV: inflammation and bone

Curr HIV/AIDS Rep. 2012 Mar;9(1):16-25. doi: 10.1007/s11904-011-0099-z.

Abstract

HIV infection and antiretroviral therapy (ART) are now established independent risk factors for osteoporosis. With a spate of recent studies reporting significant elevations in fracture prevalence in HIV patients, and a rapidly aging demographic, defining the mechanisms underlying HIV/ART-induced skeletal decline has become imperative. The recent emergence of the field of "osteoimmunology" has provided a conceptual framework to explain how the immune and skeletal systems interact. Furthermore, it is becoming clear that inflammatory states leading to perturbations in the immuno-skeletal interface, a convergence of common cells and cytokine mediators that regulate both immune and skeletal systems, conspire to imbalance bone turnover and induce osteoporosis. In this review we examine the role of inflammation in the bone loss associated with diverse inflammatory conditions and new concepts into how the underlying mechanisms by which inflammation and immune dysregulation impact bone turnover may be pertinent to the mechanisms involved in HIV/ART-induced bone loss.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications*
  • Acquired Immunodeficiency Syndrome / drug therapy
  • Acquired Immunodeficiency Syndrome / immunology
  • Acquired Immunodeficiency Syndrome / physiopathology
  • Anti-Retroviral Agents / adverse effects
  • B-Lymphocytes / immunology
  • Bone Diseases, Metabolic / etiology*
  • Bone Diseases, Metabolic / immunology
  • Bone Diseases, Metabolic / physiopathology
  • Bone Remodeling / physiology
  • HIV-1 / immunology
  • Humans
  • Inflammation / complications*
  • Inflammation / immunology
  • Inflammation / physiopathology
  • T-Lymphocytes / immunology

Substances

  • Anti-Retroviral Agents